In translational stem cell culture applications, switching from research-grade to GMP-grade reagents, or vice versa, often introduces uncertainties that can disrupt clinical progress and pluripotency.
SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (FATE) (“Fate Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback